A multicenter randomized controlled trial to assess the efficacy of cancer green therapy in treatment of stage IIIb/IV non-small cell lung cancer

Dongfang Hospital Beijing University of Chinese Medicine0 个研究点开始时间: 待定最近更新: 2023年2月20日

适应症

试验速览

暂无简介。

•(1) Patients with histologically or cytologically confirmed NSCLC, and clinical stage IIIb or IV.
•(2) One of above five TCM syndrome pattern differentiation;
•(3) There is at least one lesion larger than 2cm in diameter that can be cryoablation in the lung;
•(4) The Eastern Cooperative Oncology Group (ECOG) score <= 2 and the expected survival time was more than 3 months
•(5) Aged more than 18 years;
•(6) Able to read Chinese and willingness to provide signed informed consent.

•(1) Patients who had received any radiation, chemotherapy, targeted therapy or immunotherapy for their cancers within a month;
•(2) Patients with symptomatic brain metastases;
•(3) Patients with infectious and radioactive inflammation around the lesion, or skin infection and ulceration at the puncture site;
•(4) Patients with severe pulmonary fibrosis especially drug-induced pulmonary fibrosis;
•(5) Patients with severe bleeding tendency, platelet less than 50×109/L and severe coagulation disorders;
•(6) Patients with poor control of ipsilateral malignant pleural effusion;
•(7) Pregnant and lactating women; or severe insufficiency of liver, kidney, heart, lung and brain; or severe anemia, dehydration and serious disorders of nutrition metabolism, unable to be corrected or improved in a short time; or patients with severe systemic infection and high fever (T > 38.5 degree C).
•(8) HIV antibody positive or with other acquired or congenital immunodeficiency diseases;
•(9) Patients with a history of organ transplantation;
•(10) Patients enrolled in other clinical trials within three months.

发起方

Dongfang Hospital Beijing University of Chinese Medicine